Podium to Practice: Chicago 2025 – Lung: KRYSTAL-7

Podium to Practice: Chicago 2025 – Lung: KRYSTAL-7

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Kevin Jao

Studies / Trials Discussed

8500 – First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

This program has been made possible through unrestricted support from Boehringer Ingelheim.

Studies/trials discussed:

8500 – First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
Tagged